Fitz B. Collings

Associate | Washington, D.C. | (202) 572-6757
(202) 572-6757

Fitz Collings is an IP litigator who puts science first to develop innovative litigation strategies for life sciences and technology companies.

Fitz counsels some of the largest pharmaceutical, biotechnology, and technology companies in the world on complex intellectual property matters. His experience over the past decade includes high-profile patent litigation involving immunotherapies for autoimmune disease and cancer, for which he was recognized by Who’s Who Legal: Life Sciences in 2017 and 2018; trade-secret proceedings before the International Trade Commission; numerous Hatch-Waxman cases in district courts around the country; and representation of life sciences, biotechnology, and technology companies before the Patent and Trademark Appeal Board. Fitz also regularly serves as a trusted advisor to emerging companies—for whom IP is often their greatest asset—in structuring their growth and preparing for future litigation.

Fitz maintains an active pro bono practice in which he represents clients in Medicaid coverage disputes and immigration matters. His recent pro bono work involved representing some of the most vulnerable members of our communities in partnership with Maryland Disability Law Center, Children’s Law Center, and Public Counsel.

Fitz earned his B.A. in biology from Cornell University. He received his J.D. from the College of William & Mary, where he served as the technical editor for the Environmental Law and Policy Review and as president for both the American Constitution Society and the Student Intellectual Property Society. Prior to law school, Fitz worked as a scientific researcher at Brigham and Women’s Hospital and the Cleveland Clinic, and he draws on this experience to provide legal advice grounded in science to all of his clients.

Representative Experience

  • Representing a global pharmaceutical company in worldwide patent litigation and PTAB proceedings involving a first-in-class antibody immunotherapy product.
  • Defending a global pharmaceutical company in district court patent litigation under the BPCIA and PTAB proceedings involving a prominent biologic product.
  • Representing a global pharmaceutical company in numerous district court litigations under the Hatch-Waxman Act involving small-molecule product.
  • Representing several global pharmaceutical companies in district court litigation involving a blockbuster small molecule product.
  • Representing a global pharmaceutical company in pre-suit diligence and litigation to invalidate an antibody patent under license, securing a highly favorable settlement.
  • Representing a biotechnology company in district court litigation and PTAB proceedings regarding microfluidic devices.
  • Securing additional patent term adjustment for an antibody patent in a Section 154 proceeding against the U.S. Patent Office.
  • Defending in a reexamination proceeding a patent directed to the active ingredient of a major biologic therapy.
  • Defending a chemical manufacturer in a trade secret dispute before the International Trade Commission.
Show More


Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.